MIT-Designed Cooler Preserves Tuberculosis Drugs, Records Doses

A modified soft-drink cooler, developed by researchers at MIT’s D-Lab, could make a dent in the disease’s impact

Written byOther Author
| 4 min read
Register for free to listen to this article
Listen with Speechify
0:00
4:00

Tuberculosis, now largely controlled in the industrialized world, remains a stubbornly persistent killer in most of Africa, as well as parts of Asia and South America. The spread of multidrug-resistant strains of TB has slowed progress against the devastating disease, which is estimated to strike more than 10 million people annually. Now a modified soft-drink cooler, developed by researchers at MIT’s D-Lab, could make a dent in the disease’s impact.

There are two big issues that physicians confront in trying to tackle drug-resistant TB strains in developing countries. First, the drugs used to treat the disease, which require several doses per day over a course of 18 months, must be kept at a controlled low temperature — in places where the availability of electricity is sparse and unreliable. And second, the drugs must be taken regularly, requiring continuous monitoring by health care workers.

Both issues could potentially be addressed by the cooler developed by researchers in the Little Devices Lab, a team of researchers within D-Lab who work to develop low-cost solutions to pressing medical needs.

To continue reading this article, sign up for FREE to
Lab Manager Logo
Membership is FREE and provides you with instant access to eNewsletters, digital publications, article archives, and more.

Related Topics

CURRENT ISSUE - October 2025

Turning Safety Principles Into Daily Practice

Move Beyond Policies to Build a Lab Culture Where Safety is Second Nature

Lab Manager October 2025 Cover Image